Skip to main content

Halozyme Therapeutics, Inc.

corporate_fare Company Profile

Halozyme Therapeutics, Inc.

HALO·NASDAQ·Life Sciences·CIK 0001159036

Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on drug delivery solutions. The company developed ENHANZE drug delivery technology, which uses its proprietary enzyme, rHuPH20, to enable subcutaneous (SC) delivery of injected drugs and fluids. This technology aims to improve patient experience through rapid SC delivery and reduced treatment burden. Halozyme licenses ENHANZE to other biopharmaceutical companies to develop products combining ENHANZE with their compounds. Halozyme is also developing Hypercon drug delivery technology, an innovative microparticle technology shown in non-clinical testing to hyperconcentrate drugs and biologics, reducing injection volume for the same dosage. This could expand opportunities for at-home and healthcare provider administration. Additionally, the company is developing Surf Bio drug delivery technology to create high antibody and biologic concentrations of up to 500 mg/mL for delivery in a single auto-injector shot, for at-home or healthcare provider office use. The company also develops, manufactures, and commercializes drug-device combination products, either independently or with partners, utilizing its advanced auto-injector technologies. These products are designed to offer commercial or functional advantages like improved convenience, reliability, tolerability, enhanced patient comfort, and adherence. The ENHANZE partners' approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronan, a component of the SC space, to improve and accelerate SC delivery of high-dose, high-volume injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for HALO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for HALO spans 8-K, 144, 10-Q.

Recent high-impact activity:

  • German Appeals Court Overturns Keytruda SC Injunction; Halozyme Shares Slip
  • FDA Grants Accelerated Approval to J&J's ENHANZE-Based RYBREVANT FASPRO in Head and Neck Cancer
  • Halozyme Q3 Revenue Jumps 39% to $493M, Full-Year 2026 Guidance Raised
  • Halozyme Posts $2.01 Q3 EPS as Royalty Engine Keeps Rolling
  • Halozyme Wins Injunction Blocking Merck's Keytruda SC in Europe

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.4B
Net Income
$316.89M
Diluted EPS
$2.56
Op. Cash Flow
$651.56M
Free Cash Flow
$644.59M
Gross Profit
$1.17B
Operating Income
$469.01M
Cash & Equivalents
$133.82M
Total Debt
$2.14B
Debt / Equity
43.89×
Net Margin
22.7%
Shares Outstanding
117.78M sh
Source: 10-K · filed 2026-02-17 · accession 0001159036-26-000024

Short Interest & Short Volume

6.81 days to cover

FINRA reported short interest of 13,650,219 shares in HALO as of the October 30, 2026 settlement, unchanged from the prior period — about 6.8 days to cover at its recent average daily volume. On November 20, 2026, 46.1% of HALO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)13,650,219 shares as of October 30, 2026
Change vs prior period 0.0%
Days to cover6.81 at avg daily volume of 2,005,713
Daily short volume (FINRA facilities)46.1% of 650,581 shares on November 20, 2026
5-day average short volume41.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for HALO, detected from its recent SEC filings · based on capital-structure filings through 2026-09-18.

Upsized $1.3B Convertible Notes Priced · Conversion Terms Set at 27.5% Premium

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with H →
$91.35
52-week range · as of 2026-11-05 $61.23 – $134
Market cap
$10.41B
Volume
1.5M (0.6× avg)
3-mo avg 2.3M
Live data · 2026-11-21 23:06 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HALO - Latest Insights

HALO
Nov 19, 2026, 10:00 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $92.63
Real-time Price: $91.35 info
Change: -$1.28 (-1%) info
Market Cap: $10.415B info
HALO
Nov 06, 2026, 9:57 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $110.28
Real-time Price: $91.35 info
Change: -$18.93 (-17%) info
Market Cap: $10.415B info
HALO
Nov 05, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $114.34
Real-time Price: $91.35 info
Change: -$22.99 (-20%) info
Market Cap: $10.415B info
HALO
Nov 05, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $123.61
Real-time Price: $91.35 info
Change: -$32.26 (-26%) info
Market Cap: $10.415B info
HALO
Oct 07, 2026, 8:30 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $110.00
Real-time Price: $91.35 info
Change: -$18.65 (-17%) info
Market Cap: $10.415B info
HALO
Oct 07, 2026, 1:19 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $110.00
Real-time Price: $91.35 info
Change: -$18.65 (-17%) info
Market Cap: $10.415B info
HALO
Sep 22, 2026, 4:41 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $115.25
Real-time Price: $91.35 info
Change: -$23.90 (-21%) info
Market Cap: $10.415B info
HALO
Sep 18, 2026, 8:23 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $109.69
Real-time Price: $91.35 info
Change: -$18.34 (-17%) info
Market Cap: $10.415B info
HALO
Sep 17, 2026, 11:20 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $109.68
Real-time Price: $91.35 info
Change: -$18.33 (-17%) info
Market Cap: $10.415B info
HALO
Sep 16, 2026, 4:30 PM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $105.00
Real-time Price: $91.35 info
Change: -$13.65 (-13%) info
Market Cap: $10.415B info
HALO
Aug 17, 2026, 5:16 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $103.00
Real-time Price: $91.35 info
Change: -$11.65 (-11%) info
Market Cap: $10.415B info
HALO
Aug 11, 2026, 5:57 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $102.63
Real-time Price: $91.35 info
Change: -$11.28 (-11%) info
Market Cap: $10.415B info
HALO
Aug 06, 2026, 4:11 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $90.00
Real-time Price: $91.35 info
Change: +$1.35 (+1%) info
Market Cap: $10.415B info
HALO
Aug 06, 2026, 4:01 PM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $90.00
Real-time Price: $91.35 info
Change: +$1.35 (+1%) info
Market Cap: $10.415B info
HALO
Jul 02, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $79.45
Real-time Price: $91.35 info
Change: +$11.90 (+15%) info
Market Cap: $10.415B info
HALO
May 11, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $68.40
Real-time Price: $91.35 info
Change: +$22.95 (+34%) info
Market Cap: $10.415B info
HALO
May 11, 2026, 4:01 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $66.99
Real-time Price: $91.35 info
Change: +$24.36 (+36%) info
Market Cap: $10.415B info
HALO
May 08, 2026, 6:44 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $64.69
Real-time Price: $91.35 info
Change: +$26.66 (+41%) info
Market Cap: $10.415B info
HALO
May 07, 2026, 9:10 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $68.34
Real-time Price: $91.35 info
Change: +$23.01 (+34%) info
Market Cap: $10.415B info
HALO
Apr 30, 2026, 8:12 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $63.47
Real-time Price: $91.35 info
Change: +$27.88 (+44%) info
Market Cap: $10.415B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets